Addressing challenges in AAV manufacturing scale-up for cost-effective gene therapies

“Currently approved therapies have a very high price, and much of that is driven by the expensive raw materials and costly manufacturing processes.”

Jokūbas Leikauskas, Editor, BioInsights, speaks to Andrew D Tustian, Executive Director, Preclinical Manufacturing and Process Development, Regeneron, about the advancements in AAV process development from preclinical to commercial stages, addressing challenges in scaling, automation, and cost reduction, while prioritizing the delivery of innovative gene therapies to patients.

Please enter your email to access content Read now